Jim Cramer on Merck & Co.: "This Is One of My Favorite Pharmaceutical Stocks"

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer looked at recently. Cramer discussed the company’s latest quarter, as he commented:

This morning, Merck reported a very solid quarter, but gave what some people thought was a soft full-year forecast, yet the stock finished up the session more than 2%. Why? Because investors realized that the guidance was dragged down by one time costs related to a big acquisition last year. How could they not know that? This is one of my favorite pharmaceutical stocks.

Merck & Co., Inc. (NYSE:MRK) is a healthcare company that provides a wide range of human and veterinary pharmaceuticals, vaccines, and health solutions. Cramer mentioned the stock during his game plan presented on the January 30 episode. The Mad Money host said:

Merck has a lot to talk about, namely, some real wins from its bountiful acquisition spree. I like the stock. A little too heavy on Keytruda right now, but I think it can spread out the wealth.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.